204 related articles for article (PubMed ID: 20227784)
1. Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
Trani L; Myerson J; Ashley S; Young K; Sheri A; Hubner R; Puglisi M; Popat S; O'Brien ME
Lung Cancer; 2010 Nov; 70(2):200-4. PubMed ID: 20227784
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
3. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
4. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Lorusso V; Crucitta E; Panza N; Silvestris N; Guida M; Carpagnano F; Mancarella S; Sambiasi D; De Lena M
Ann Oncol; 2002 Dec; 13(12):1862-7. PubMed ID: 12453853
[TBL] [Abstract][Full Text] [Related]
6. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.
Petrioli R; Francini E; Fiaschi AI; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Bianco V; Roviello G
Med Oncol; 2015 Apr; 32(4):134. PubMed ID: 25796503
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
[TBL] [Abstract][Full Text] [Related]
9. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.
Fløtten Ø; Grønberg BH; Bremnes R; Amundsen T; Sundstrøm S; Rolke H; Hornslien K; Wentzel-Larsen T; Aasebø U; von Plessen C
Br J Cancer; 2012 Jul; 107(3):442-7. PubMed ID: 22759880
[TBL] [Abstract][Full Text] [Related]
10. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
[TBL] [Abstract][Full Text] [Related]
11. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Vansteenkiste J; Barlesi F; Waller CF; Bennouna J; Gridelli C; Goekkurt E; Verhoeven D; Szczesna A; Feurer M; Milanowski J; Germonpre P; Lena H; Atanackovic D; Krzakowski M; Hicking C; Straub J; Picard M; Schuette W; O'Byrne K
Ann Oncol; 2015 Aug; 26(8):1734-40. PubMed ID: 25939894
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP
Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
[TBL] [Abstract][Full Text] [Related]
15. Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
Dong X; Zhao X; Hao Y; Wei Y; Yin Q; Du J
Clin Lung Cancer; 2013 Nov; 14(6):680-7. PubMed ID: 23910066
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
Hasturk S; Hatabay N; Ece F; Karatasli M; Hanta I
Am J Clin Oncol; 2009 Jun; 32(3):280-5. PubMed ID: 19433960
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
[TBL] [Abstract][Full Text] [Related]
18. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
19. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Brunetto AT; Carden CP; Myerson J; Faria AL; Ashley S; Popat S; O'Brien ME
J Thorac Oncol; 2010 Sep; 5(9):1397-403. PubMed ID: 20644495
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]